Relevance. The relevance of the problem is in the high prevalence of the herpes simplex virus. According to WHO, nearly 90% of the population are carriers. Relapses can occur several times a year, which leads to disability and impairs the quality of life. Currently, there are a large number of drugs for general and local treatment. However, they are toxic and can cause allergic reactions. In recent years, a large number of studies have been devoted to the use of lasers in the treatment of dental diseases. Therefore, the question of the use of a laser in the treatment of herpetic lesions of the oral cavity remains relevant.Purpose. The research purpose was to determine the effectiveness of the use of a diode laser in the treatment of herpetic lesions of the lips.Materials and methods. We conducted a comparative assessment of the effectiveness of the use of a diode laser in monotherapy of herpetic lip lesions in 18 patients. The comparison group consisted of 18 patients, in the local treatment of which antiviral ointments were used.Results. The results of the study showed that the use of a diode laser can reduce treatment time, accelerate the epithelization of foci.Conclusion. The results of our study allow us to recommend the use of a diode laser in the complex treatment of herpetic lesions of the oral cavity.

No abstract

The purpose — to determine the role of the relationship between the number and aggregation capacity of platelets (Tr) with the process of lipid peroxidation (POL) in the natural course of chronic hepatitis C (HCV). Material and methods. 332 patients with HCV were observed, divided into three groups according to the phases of disseminated intravascular coagulation and the number of Tr: the first group — the hypercoagulation phase (Tr > 330 x 109/l, n = 22); the second — the transition phase (Tr from 330 to 200 x 109/L, n = 132); the third — hypocoagulation (Tr < 200 x 109/L, n = 178). The vascular-platelet link of hemostasis was evaluated by the number and degree of maximum amplitude (MA) of spontaneous Tr aggregation. The POL process was studied by medium-weight molecules (MSM), malonic dialdehyde (MDA), and enzymes — superoxide dismutase (SOD), reduced (VG) and oxidized (OG) glutathione. Results. The decrease in the number of Trs against the background of prolonged infection with the hepatitis C virus was accompanied by a decrease in the antioxidant potential, an increase in the intensity of lipoperoxidation and an increase in the ability of Tr to aggregate, especially pronounced in the phase of hypocoagulation. Correlations were revealed: the numbers Tr showed inverse correlation with the levels of SOD, MSM, MDA, OG and direct correlation with VG; MA of spontaneous aggregation Tr showed direct correlation with MSM, MDA, SOD, OG and inverse correlation with VG. Conclusions. Changes in the number and aggregation ability of Tr, the level of POL products in the course of the natural course of HCV, in parallel with the ALT enzyme, reflect the activity of the infectious process. The number and MA of spontaneous Tr aggregation in patients with natural HCV with exacerbation of the disease correlate with a reduced antioxidant potential and increased intensity of lipoperoxidation. The natural course of HCV is characterized by a multidirectional change in the AOS enzymes – an increase in the SOD level and a decrease in the amount of reduced glutathione with a simultaneous increase in the oxidized one.

ЭФФЕКТИВНОСТЬ И БЕЗОПАСНОСТЬ ПРИМЕНЕНИЯ ОТЕЧЕСТВЕННОГО ЦЕПЭГИНТЕРФЕРОНА АЛЬФА-2B В ТЕРАПИИ ХРОНИЧЕСКОГО ГЕПАТИТА С. ОПЫТ РЕАЛЬНОЙ КЛИНИЧЕСКОЙ ПРАКТИКИВ настоящее время для лечения хронического гепатита С (ХГС) используют как безинтерфероновые, так и интер-феронсодержащие схемы противовирусной терапии. Последние достаточно широко используются в России за счет доступности препаратов интерферона широким слоям населения. С 2013 г. в клинической практике используется оригинальный российский препарат -цепэгинтерферон альфа-2b (цепэгИФН альфа-2b; торговая марка «Альге-рон», «Биокад», Россия). Целью настоящего исследования являлась оценка эффективности и безопасности цепэг-ИФН альфа-2b при его применении с рибавирином для лечения пациентов с ХГС. Исследование было проведено в 2014-2016 гг., в нем приняли участие 37 пациентов с ХГС (генотип вируса 1): 22 мужчины и 15 женщин (средний возраст -42,0 ± 5,2 года). Все они впервые получали комбинированную противовирусную терапию (ПВТ): цепэгИФН альфа-2b в дозе 1,5 мкг/кг/нед. и рибавирин в дозе 15 мг/кг/сут. в течение 48 недель. Эффективность ПВТ оценивали по частоте достижения устойчивого вирусологического ответа (УВО) -авиремии через 24 недели после ПВТ. В на-шем исследовании УВО достигли 26 пациентов (70,3 %). Зарегистрированные на фоне ПВТ нежелательные явления были характерными для интерферона и рибавирина. Дозу цепэгИФН альфа-2b в связи с развитием нейтропении корректировали 2 пациентам, дозу рибавирина в связи с развитием анемии -3 пациентам. Полученные результаты позволяют рекомендовать цепэгИФН альфа-2b для включения в схемы комбинированной противовирусной терапии для лечения больных с ХГС.Ключевые слова: хронический гепатит C, вирус гепатита C, противовирусная терапия, цепэгинтерферон альфа-2b, рибавирин, вирусологический ответ, эффективность лечения EFFECTIVENESS AND SAFETY OF TREATMENT WITH DOMESTIC CEPEGINTERFERON ALPHA-2B IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION. ACTUAL CLINICAL EXPERIENCEInterferon-based regimens for chronic hepatitis C (HCV) are quite common, just like interferon-free treatments, and are extensively used in Russia because interferon is widely available to most patients. In 2013 the original Russian drug cepeginterferon alpha-2b (cepegIFN alpha-2b marketed as Algeron by Biocad, Russia) was introduced into clinical practice. The aim of this study was to assess effectiveness and safety of cepegIFN alpha-2b as part of the combination therapy with ribavirin in patients with chronic HCV infection. The study was conducted over the period from 2014 to 2016 and recruited 37 patients with chronic genotype 1 HCV infection: 22 men and 15 women (mean age of 42.0 ± 5.2 years). All of them received the following combination antiviral therapy (AT): 1.5 µg/kg cepegIFN alpha-2b once a week and 15 µg/kg ribavirin daily over the period of 48 weeks. Effectiveness of AT was assessed by the rate of sustained virological response (SVR), i. e. aviremia achieved 24 weeks after the onset of treatment. In our SVR was observed in 26 patients (70.3 %). Adverse effect...